OSLO, May 12 (Reuters) - Weight-loss and diabetes drug

maker Novo Nordisk will engage with the U.S.

government over U.S. policy proposals to bring down prices, the

Danish company said in a statement to news agency Ritzau on

Monday.

"We agree that Americans need access to medicines at better

prices, and we will continue to engage with policymakers to

develop and implement more effective solutions," Ritzau quoted

Novo Nordisk as saying.